Pharmacy Grand Rounds

The tXa Files: Bleeding Management with Tranexamic Acid

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)
MN-RO-AL-MN-459-MAYO LH

Interactive Video Conference Room(s): 
MN-RO-GO-19-101 BARRETTE LH

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Tranexamic acid has been used for a wide variety of indications since its development in 1962 and subsequent FDA approval in 1986. Over the last decade, new data has surfaced illustrating the potential benefits and harms of tranexamic acid in a wide variety of different bleeding indications. The mixed data for varying indications has led to uncertainty on when tranexamic acid is appropriate and its use should be advocated for. This presentation will review some of the major indications tranexamic acid is being evaluated in by highlighting trials that both support or refute its use in said populations.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Discuss pharmacological characteristics of tranexamic acid
2. Compare and contrast primary literature for proposed tranexamic acid indications
3. Identify pharmacotherapy pearls related to tranexamic acid

Session Announcement

Session Slides

FACULTY INFORMATION

Nicholas J. Vollmer, PharmD
PGY1 Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Nick received a Doctor of Pharmacy degree from Drake University in Des Moines, IA and is currently a PGY1 Pharmacy Resident at Mayo Clinic Hospital-Rochester.  His practice interests include critical care and emergency medicine.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Nicholas J. Vollmer, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Tranexamic acid

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS